Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
Key Highlights
- ➤Myriad sells Prenatal Health testing business to Labcorp for $210 million cash plus inventory value
- ➤Labcorp expects approximately $160 million first-year revenue from the acquired business
- ➤Labcorp expects slight adjusted earnings accretion in year one
- ➤Labcorp expects acquired diagnostics margins to reach segment average by end of year two
- ➤Transaction requires regulatory clearance and is expected to close by early 2027
Expert Statements
Sam Raha, President and CEO of Myriad Genetics
“This announcement is the direct outcome of our disciplined strategic review process, which is focused on sharpening our portfolio, enhancing operational execution and driving shareholder value.”
Sam Raha, President and CEO of Myriad Genetics
“This transaction is expected to be accretive to Myriad’s revenue growth and profitability, while meaningfully strengthening the balance sheet to support continued investment in our strategic priorities tied to the cancer care continuum and long-term value creation.”
Sam Raha, President and CEO of Myriad Genetics
“Working closely with Labcorp, one of the nation’s largest laboratory service providers, we expect a smooth transition that preserves uninterrupted patient access to our prenatal tests.”
Bryan Vaughn, Executive Vice President and President of Diagnostics at Labcorp
“This transaction supports Labcorp's specialty testing growth strategy”
Bryan Vaughn, Executive Vice President and President of Diagnostics at Labcorp
“Myriad Genetics has built a highly complementary reproductive genetics platform, supported by innovative screening solutions and deep scientific expertise. By combining these capabilities with Labcorp's operational strength and high-quality women's health portfolio, we aim to improve outcomes, expand access to advanced screening solutions and enhance the patient and provider experience.”
SALT LAKE CITY and BURLINGTON, N.C., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, and Labcorp (NYSE: LH), a global leader in innovative and comprehensive laboratory services, today announce they have entered into a definitive agreement for Myriad to sell its Prenatal Health testing business, which includes the Prequel(®), Foresight(®), SneakPeek(®), and FirstGene(®) tests, to Labcorp for $210 million in cash, plus the value of the inventory of the Prenatal Health testing business at closing.
“This announcement is the direct outcome of our disciplined strategic review process, which is focused on sharpening our portfolio, enhancing operational execution and driving shareholder value,” said Sam Raha, President and CEO, Myriad Genetics. “This transaction is expected to be accretive to Myriad’s revenue growth and profitability, while meaningfully strengthening the balance sheet to support continued investment in our strategic priorities tied to the cancer care continuum and long-term value creation. Working closely with Labcorp, one of the nation’s largest laboratory service providers, we expect a smooth transition that preserves uninterrupted patient access to our prenatal tests.”
Get started
Create a free account to read the full story.